专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明申请

WO2010039931A3 METHODS OF USING IL17RD AND IL23-IL17 PATHWAY GENES TO DIAGNOSE CROHN'S DISEASE 审中-公开
标题翻译：使用IL17RD和IL23-IL17途径基因诊断克罗恩病的方法
公开(公告)号：WO2010039931A3
公开(公告)日：2010-06-03
申请号：PCT/US2009059190
申请日：2009-10-01
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , MCGOVERN DERMOT P , MEI LING
发明人： ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , MCGOVERN DERMOT P , MEI LING
IPC分类号： G01N33/48 , G01N33/50
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： Disclosed are methods of diagnosing susceptibility to Crohn's Diseaese by determining the presence or absence of susceptibility vanants at the ILI7RD locus Also disclosed is a method of diagnosing and/or predicting susceptibility to Crohn's Disease by determining the presence or absence of an interaction between ILI7RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IU2RB2 Haplotype 4, where the presence of an interaction between IL17RD Block 2 Haplotype 2 and IL23R Block 2 Haplotype 2 and/or IL12RB2 Haplotype 4 is indicative of susceptibility to Crohn's Disease.
摘要翻译：公开了通过确定在ILI7RD基因座上存在或不存在易感性的方法来诊断对克罗恩病的敏感性的方法还公开了通过确定ILI7RD Block2（ILI7RD Block2）之间存在或不存在相互作用的方法来诊断和/或预测对克罗恩病的易感性单体型2和IL23R Block 2单倍型2和/或IU2RB2单倍型4，其中IL17RD Block2单倍型2和IL23R Block 2单倍型2和/或IL12RB2单倍型4之间的相互作用的存在表明对克罗恩病的易感性。

82. 发明申请

WO2008141148A3 CHARACTERIZATION OF THE CBIR1 ANTIGENIC RESPONSE FOR DIAGNOSIS AND TREATMENT OF CROHN'S DISEASE 审中-公开
标题翻译： CBIR1抗原反应诊断和治疗癌症的特征
公开(公告)号：WO2008141148A3
公开(公告)日：2009-01-15
申请号：PCT/US2008063202
申请日：2008-05-09
申请人： CEDARS SINAI MEDICAL CENTER , UAB RESEARCH FOUNDATION , TAYLOR KENT D , ROTTER JEROME I , TARGAN STEPHAN R , ELSON CHARLES O
发明人： TAYLOR KENT D , ROTTER JEROME I , TARGAN STEPHAN R , ELSON CHARLES O
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/112 , C12Q2600/156 , C12Q2600/172
摘要： This invention provides methods of diagnosing or predicting susceptibility to Crohn's Disease by determining the presence or absence of genetic variants. In one embodiment, the present invention provides methods to diagnose and/or predict susceptibility to Crohn's Disease in an individual by determining the presence or absence of anti-Cbir1 reactivity and the presence or absence of TLR5 risk variants. In another embodiment, the present invention provides methods to diagnose Crohn's Disease by determining the presence or absence of NFKB1 haplotype H3 and/or ASCA expression. In another embodiment, the present invention provides methods of diagnosing Crohn's Disease by determining the presence or absence of Cbir1 specific peripheral blood T cell proliferation.
摘要翻译：本发明提供通过确定遗传变异体的存在或不存在来诊断或预测克罗恩病易感性的方法。在一个实施方案中，本发明提供了通过确定抗Cbir1反应性的存在或不存在以及是否存在TLR5风险变体来诊断和/或预测个体中克罗恩病易感性的方法。在另一个实施方案中，本发明通过确定NFκB1单倍型H3和/或ASCA表达的存在或不存在来提供诊断克罗恩病的方法。在另一个实施方案中，本发明通过确定Cbir1特异性外周血T细胞增殖的存在或不存在来提供诊断克罗恩病的方法。

83. 发明申请

WO2008109782A2 DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN CHILDREN 审中-公开
标题翻译：诊断儿童中的炎症性皮肤病
公开(公告)号：WO2008109782A2
公开(公告)日：2008-09-12
申请号：PCT/US2008056103
申请日：2008-03-06
申请人： CEDARS SINAI MEDICAL CENTER , DUBINSKY MARLA , TARGAN STEPHAN R , ROTTER JEROME I
发明人： DUBINSKY MARLA , TARGAN STEPHAN R , ROTTER JEROME I
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156
摘要： This invention provides methods of diagnosing and predicting disease progression of Crohn's disease. In one embodiment, a method of the invention is practiced by determining the presence or absence of CARD15 variants R702W, G908R, and/or 1007insC in a pediatric individual. In another embodiment, a method of the invention is practiced by determining the presence or absence of anti-Cbir1, anti-OmpC, ASCA, and/or pANCA in a pediatric individual
摘要翻译：本发明提供诊断和预测克罗恩病疾病进展的方法。在一个实施方案中，通过在儿科个体中确定CARD15变体R702W，G908R和/或1007insC的存在或不存在来实施本发明的方法。在另一个实施方案中，本发明的方法通过确定儿科个体中抗Cbir1，抗OmpC，ASCA和/或pANCA的存在或不存在来实施

84. 发明申请

WO2004091372A3 METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE 审中-公开
标题翻译：通过I2，OMPC和ASCA行为反应来评估冠心病患者的方法
公开(公告)号：WO2004091372A3
公开(公告)日：2005-02-10
申请号：PCT/US2004011227
申请日：2004-04-09
申请人： CEDARS SINAI MEDICAL CENTER , TARGAN STEPHAN R , VASILIAUSKAS ERIC A , MOW WILLIAM S , YANG HUIYING , FLESHNER PHILLIP R , ROTTER JEROME I
发明人： TARGAN STEPHAN R , VASILIAUSKAS ERIC A , MOW WILLIAM S , YANG HUIYING , FLESHNER PHILLIP R , ROTTER JEROME I
IPC分类号： A61B20060101 , C12Q1/68 , G01N33/53
CPC分类号： C12Q1/6883 , G01N2800/065
摘要： The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-Saccharomyces cerevisiae antibodies (ASCA), IgA anti-OmpC antibodies, or perinuclear anti-neutrophil cytoplasmic antibodies (pANCA). The methods of the invention can be used to diagnose or predict susceptibility to a clinical subtype of Crohn's disease, for example, a fibrostenotic subtype, a subtype characterized by the need for small bowel surgery, or a subtype characterized by the absence of features of ulcerative colitis.
摘要翻译：本发明提供一种诊断或预测克罗恩病临床亚型易感性的方法，其通过测定受试者中IgA抗-I2抗体的存在或不存在，其中IgA抗-I2抗体的存在表明该受试者具有克罗恩病的临床亚型。在一个实施方案中，通过进一步确定受试者中NOD2变体，抗酿酒酵母抗体（ASCA），IgA抗OmpC抗体或核周抗中性粒细胞胞质抗体（pANCA）的存在或不存在来实施本发明的方法）。本发明的方法可以用于诊断或预测对克罗恩病的临床亚型的易感性，例如纤维狭窄亚型，特征在于需要小肠手术的亚型或特征在于不存在溃疡特征的亚型结肠炎。

85. 发明申请

WO2012135146A2 ROLE OF IFNG METHYLATION IN INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： IFNG甲基化在炎症性皮肤病中的作用
公开(公告)号：WO2012135146A2
公开(公告)日：2012-10-04
申请号：PCT/US2012030616
申请日：2012-03-26
申请人： CEDARS SINAI MEDICAL CENTER , GONSKY REBECCA , DEEM RICHARD , TARGAN STEPHAN R
发明人： GONSKY REBECCA , DEEM RICHARD , TARGAN STEPHAN R
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/154 , C12Q2600/156 , C12Q2600/158
摘要： The invention relates to method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation. In one embodiment, the present invention provides a method of diagnosing susceptibility to inflammatory bowel disease (IBD) in an individual by obtaining a sample from the individual, assaying the sample to determine the presence or absence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject, and diagnosing susceptibility to inflammatory bowel disease based on the presence of one or more risk genetic variants and/or an increase in IFNG DNA methylation relative to a normal subject. In another embodiment, the IBD is ulcerative colitis.
摘要翻译：本发明涉及通过从个体获得样品来诊断对个体的炎性肠病易感性（IBD）的方法，测定样品以确定一种或多种风险遗传变异体的存在或不存在和/或IFNG DNA的增加甲基化。在一个实施方案中，本发明提供了通过从个体获得样品来诊断个体中对炎症性肠病（IBD）的易感性的方法，测定样品以确定是否存在一种或多种风险遗传变体和/或相对于正常受试者，IFNG DNA甲基化的增加，以及基于一种或多种风险遗传变异体的存在和/或IFNG DNA甲基化相对于正常受试者的增加诊断对炎性肠病的易感性。在另一个实施方案中，IBD是溃疡性结肠炎。

86. 发明申请

WO2010075579A3 METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (MR-UC) REQUIRING COLECTOMY 审中-公开
标题翻译：预防药物回顾性检查（MR-UC）要求的方法
公开(公告)号：WO2010075579A3
公开(公告)日：2010-10-14
申请号：PCT/US2009069531
申请日：2009-12-24
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , HARITUNIANS TALIN , MCGOVERN DERMOT P
发明人： ROTTER JEROME I , TAYLOR KENT D , TARGAN STEPHAN R , HARITUNIANS TALIN , MCGOVERN DERMOT P
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156 , G01N2800/067
摘要： Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
摘要翻译：公开了预测患者医学难治性溃疡性结肠炎（MR-UC）的发展的方法。在一个实施方案中，公开了通过确定一种或多种风险变体的存在或不存在来预测个体中的溃疡性结肠炎的方法，其中一种或多种风险变体的存在指示溃疡性结肠炎的严重和/或侵略性形式。在另一个实施方案中，严重形式的溃疡性结肠炎指示MR-UC。

87. 发明申请

WO2008106451A3 METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE 审中-公开
标题翻译： TL1A基因单核苷酸多态性预测或诊断炎性肠病的方法
公开(公告)号：WO2008106451A3
公开(公告)日：2008-11-06
申请号：PCT/US2008055020
申请日：2008-02-26
申请人： CEDARS SINAI MEDICAL CENTER , ROTTER JEROME I , TAYLOR KENT D , DUBINSKY MARLA , TARGAN STEPHAN R
发明人： ROTTER JEROME I , TAYLOR KENT D , DUBINSKY MARLA , TARGAN STEPHAN R
IPC分类号： C12Q1/68 , A01N43/04 , C12M1/34 , C12N15/00
CPC分类号： C12Q1/6883 , C07K16/2875 , C07K2317/76 , C12Q2600/112 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/6893 , G01N2800/065 , G01N2800/50
摘要： This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
摘要翻译：本发明提供了通过确定TL1A基因中是否存在遗传变异来诊断或预测炎性肠病易感性的方法。在一个实施方案中，本发明的方法通过测定Fc-γ-R活化后TL1A产生的存在或不存在来实施。在另一个实施方案中，本发明提供了通过抑制TL1A来治疗炎症性肠病的方法。

88. 发明申请

WO2007117611A3 ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE 审中-公开
标题翻译：增强T细胞受体介导的肿瘤坏死因子超家族和CHEMOKINE在外周血白细胞介素的表达与患有慢性疾病的患者
公开(公告)号：WO2007117611A3
公开(公告)日：2008-08-07
申请号：PCT/US2007008597
申请日：2007-04-05
申请人： HITACHI CHEMICAL CO LTD , HITACHI CHEMICAL RES CT INC , CEDARS SINAI MEDICAL CENTER , MITSUHASHI MASATO , TARGAN STEPHAN R
发明人： MITSUHASHI MASATO , TARGAN STEPHAN R
IPC分类号： G01N33/53
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/158
摘要： A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed.
摘要翻译：公开了一种用于通过测量响应于刺激的某些mRNA的水平来确定克罗恩病患者是否可能对靶向TNFSF成员或细胞因子的治疗作出反应的方法。还公开了评估人类克罗恩病治疗有效性的方法。此外，公开了一种筛选用于治疗克罗恩病的化合物的方法。还公开了一种在克罗恩病患者中随时间监测疾病状态的方法。

89. 发明申请

WO0189361A2 DIAGNOSIS, PREVENTION AND TREATMENT OF CROHN'S DISEASE USING THE OMPC ANTIGEN 审中-公开
标题翻译：使用OMPC抗原诊断，预防和治疗胆囊疾病
公开(公告)号：WO0189361A2
公开(公告)日：2001-11-29
申请号：PCT/US0116032
申请日：2001-05-17
申请人： CEDARS SINAI MEDICAL CENTER , UNIV CALIFORNIA , TARGAN STEPHAN R , BRAUN JONATHAN , SUTTON CHRISTOPHER L
发明人： TARGAN STEPHAN R , BRAUN JONATHAN , SUTTON CHRISTOPHER L
IPC分类号： G01N33/53 , A61K39/108 , A61P1/04 , C12N15/09 , G01N33/543 , G01N33/569 , G01N33/68 , A61B
CPC分类号： G01N33/56972 , G01N33/6854 , G01N2333/195 , G01N2333/245 , G01N2333/395 , G01N2469/20 , Y10S435/849 , Y10S435/965 , Y10S435/973 , Y10S436/811
摘要： The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence of IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.
摘要翻译：本发明提供了一种通过测定受试者中存在或不存在IgA抗OmpC抗体来诊断受试者中的克罗恩病的方法，其中IgA抗OmpC抗体的存在表明受试者患有克罗恩氏病。

90. 发明申请

WO2014186665A2 DISTINCT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A MODULATED INFLAMMATION AND FIBROSIS 审中-公开
标题翻译： IFN-GAMMA和IL-17对TL1A调节性炎症和纤维化的不同作用
公开(公告)号：WO2014186665A2
公开(公告)日：2014-11-20
申请号：PCT/US2014038333
申请日：2014-05-16
申请人： CEDARS SINAI MEDICAL CENTER
发明人： SHIH DAVID Q , TARGAN STEPHAN R , BILSBOROUGH JANINE
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , G01N33/6893 , G01N2333/525 , G01N2333/54 , G01N2333/57 , G01N2800/065
摘要： Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject.
摘要翻译：本文描述的是与炎症性肠病相关的方法和组合物。特别是TL1A驱动局部肠道炎症和纤维化，并被IFNγ和IL-17a差异调节。在一个实施方案中，本发明是通过确定IFNγ和/或IL-17的存在或不存在并诊断受试者来诊断受试者中的状况的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式